Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma

Cancer

Volumn 86, Issue 3, 1999, Pages 463-469

  Egawa, Shin ^a   Matsumoto, Kazumasa ^a   Suyama, Kazuho ^a   Iwamura, Masatsugu ^a   Kuwao, Sadahito ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical significance; Natural history; Prostate carcinoma; Prostate specific antigen; Prostate specific antigen doubling time; Racial difference; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE COURSE; HUMAN; HUMAN TISSUE; INCIDENCE; JAPAN; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RACE DIFFERENCE;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; JAPAN; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0033178796     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990801)86:3<463::AID-CNCR14>3.0.CO;2-2     Document Type: Article

References (31)

1. The Research Group for Population-Based Cancer Registration in Japan. Cancer incidence in Japan in 1990: estimates based on data from population-based cancer registries. Jpn J Clin Oncol 1998;28:574-7.
2. Tominaga S, Aoki K, Hanai A, Kurihara N. Cancer statistics-incidence/-mortality/-prognosis, 1993 [in Japanese]. Tokyo: Shinohara Publishing Co., 1993;154-70 (in Japanese).
3. Egawa S, Suyama K, Ohori M, Kawakami T, Kuwao S, Hirokado K, et al. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer 1995;76:463-72.
4. Fowler JE Jr., Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol 1996;156: 133-6.
5. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobsen DJ, McLeod DG, Moul JW. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 1996;335:304-10.
6. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-9.
7. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937-40.
8. Egawa S, Satoh T, Suyama K, Iwamura M, Uchida T, Koshiba K. Risk of progression and dying of clinically localized prostate cancer in Japan. World J Urol 1996;14:363-9.
9. Urological tumors - prostate. In: Sobin LH, Wittekind CH, editors. International Union Against Cancer. TNM classification of malignant tumors, 5th edition. New York: John Wiley & Sons, Inc., 1997:170-3.
10. Machida T, Ohishi Y, Wada T, Akimoto S, Shimazaki J, Oda H, et al. Clinical evaluation of a new kit (IMx PA Dainapack) for detection of serum prostate specific antigen. Acta Urol Japonica 1993;39:977-84.
11. Arai T, Tsukada T, Nakayama T. Evaluation of AxSYM automated immunoassay analyzer system for determining prostate-specific antigen, and comparison of reactivities for the antigen and diagnostic values of several commercial kits. J Med Pharmacol Sci 1994;32:125-36.
12. Egawa S, Suyama K, Matsumoto K, Satoh T, Uchida T, Kuwao S, et al. Improved predictability of extracapsular extension and seminal vesicle involvement based on biopsy findings in Japanese prostate cancer. Urology 1998;52:433-40.
13. Adolfsson J, Steineck G, Hedlund P-O. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology 1997;50:722-6.
14. Stenman U-H, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
15. Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6.
16. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998;82:342-8.
17. Nam RK, Klotz LH, Jewett MAS, Danjoux C, Trachtenberg J. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a "rapid riser" subset. Br J Urol 1998;81:100-4.
18. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52:3323-8.
19. Lee WR, Hanks GE, Corn BW, Schultheiss TE. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys 1995;31:21-4.
20. Hanks GER, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996;34:549-53.
21. Akimoto S, Masai M, Akakura K, Shimazaki J. Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 1995;27:207-12.
22. Bangma CH, Hop WCJ, Schroder FH. Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NXM0, Grades 1 to 3) carcinoma of the prostate. J Urol 1995;154:1403-6.
23. Goluboff ET, Heitjan DF, deVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J Urol 1997;158:1876-9.
24. Gerber GS, Gornik HL, Goldfischer ER, Chodak GW, Rukstalis DB. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol 1998;159:1243-6.
25. Schmid H-P, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40.
26. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72:2638-43.
27. Zaridze DG, Boyle P. Cancer of the prostate: epidemiology and aetiology. Br J Urol 1987;59:493-502.
28. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-94.
29. Egawa S, Matsumoto K, Iwamura M, Uchida T, Kuwao S, Koshiba K. Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan. Jpn J Clin Oncol 1997;27:394-400.
30. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume, and benign hyperplasia. J Urol 1990;143:747-52.
31. Montgomery BT, Young CYF, Builhartz DL, Andrews PE, Prescott JL, Thompson NF, et al. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line LNCaP. Prostate 1992; 21:63-73.